Psychiatric drugs ‘as effective as other drugs’ Psychiatric drugs ‘as effective as other drugs’

Psychiatric drugs are as effective as drugs used to treat many physical health problems, according to a major review published in the February issue of the British Journal of Psychiatry.
01 February 2012

Scientists reveal first 3D image of cancer-prevention molecule Scientists reveal first 3D image of cancer-prevention molecule

Cancer Research UK scientists have created the first 3D structure of a key protein that protects against the development of cancer, according to research published in Nature Structural & Molecular Biology.
23 January 2012

Rapid rise in opioid abuse is among the challenges faced by pain therapy drug developers Rapid rise in opioid abuse is among the challenges faced by pain therapy drug developers

Pain therapy drug developers address the rapid rise in prescription drug abuse alongside the need for safe and effective treatments for a growing number of chronic pain sufferers. The sector has a diverse pipeline, with reformulations of existing therapies and alternative modes of drug delivery in development alongside novel compounds. However, increased generic competition will temper market growth over the next decade.
23 January 2012

Charity bids to rid Africa of blinding disease Charity bids to rid Africa of blinding disease

Development charity Sightsavers has today unveiled a 10-year campaign to help eliminate one of the world’s leading causes of preventable blindness, termed onchocerciasis (also river blindness). With plans to fundraise and invest more than £27 million over the next decade to help combat this neglected tropical disease (NTD) across Africa, the charity is starting work this month in the Democratic Republic of the Congo where the disease is endemic.
17 January 2012

Reprogrammed oestrogen binding linked to more aggressive breast cancer Reprogrammed oestrogen binding linked to more aggressive breast cancer

Scientists based at Cancer Research UK’s Cambridge Research Institute have discovered how receptors for the female sex hormone oestrogen attach to a different part of the DNA in breast cancer patients who are more likely to relapse, according to a study published in Nature.
05 January 2012

UK Biobank: launch of procedures for accessing the resource UK Biobank: launch of procedures for accessing the resource

UK Biobank launches its Access Procedures today (Wednesday 14th), which govern the way the resource can be used by scientists to improve the health of future generations.
14 December 2011

Treatment With 'Januvia'® (sitagliptin) Associated With Fewer Major Cardiovascular Events In People With Type 2 Diabetes Compared With A Sulphonylurea Treatment With 'Januvia'® (sitagliptin) Associated With Fewer Major Cardiovascular Events In People With Type 2 Diabetes Compared With A Sulphonylurea

A new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE) compared to those treated with a sulphonylurea (SU).
06 December 2011

Pantarhei Bioscience announces discovery of antigen (ZP3) as a treatment to combat ovarian cancer Pantarhei Bioscience announces discovery of antigen (ZP3) as a treatment to combat ovarian cancer

Pantarhei Bioscience, a specialty pharmaceutical company focusing on the development of innovative, proprietary treatments in the fields of women’s health and endocrine cancer, announces the publication in the Journal of the Federation of American Societies for Experimental Biology (FASEB J October 5, 2011) of the results of an innovative treatment strategy for ovarian cancer, which has now been selected to appear in the Faculty of 1000 (F1000) emphasizing its significance.
15 November 2011

World’s first stem cell bandage in human clinical trials World’s first stem cell bandage in human clinical trials

The company behind a pioneering stem cell bandage, believed to be the world’s first adult and autologous (patient’s own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK’s most successful entrepreneurs.
14 November 2011

Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology

Almac’s Diagnostics business unit today announced the publication of its stage II colon cancer recurrence signature (diagnostic test) in the Journal of Clinical Oncology.
08 November 2011